Transcript Britton Chance: The Development of In Vivo MRS Mitchell Schnall MD, PhD.

Britton Chance: The
Development of In Vivo MRS
Mitchell Schnall MD, PhD
Metabolism as a basis for
understanding and curing disease
4 degrees C
Warm Ischemia
75 second spectrum
Exercising in the NMR magnet
The Transfer function: “Furthermore, the slope and extent
of the linear portion of Fig. 4 are pivotal in the identification of normal and
pathological functions of the limb.”
Figure 4
Assuming ADP control and MichaelisMenten kinetics
assuming a constant pH of 7.1, a temperature of
370C, a 1.0-mM magnesium concentration, and a
5-mM ATP concentration giving Kobs, = 132 (1)
and Km ADP = 20 AM (19, 24).
Vmax of 52 J/min and a Km of 0.65 ± 0.06.
PFK
Recovery kinetics as a Biomarker
PFK deficient
PVD patient
Vitamin K3
Vitamin C
Detecting Treatment Response
Patient prior to (A)
and after (B) therapy
Normal Subject
0
5
Min
10
1985
BC’s Contribution to MRS
• Established feasibility to real time measurement of metabolites in
perfused organs, intact animal models, and humans
• Developed a mechanistic approach to interpretation of spectral data for
the purpose of clinical diagnostics
• Developed a strategy of using MRS as a pharmaco-dynamic marker of
treatment effect
• Established the role of PME (choline in the proton spectrum) as an
important marker of malignancy
• Inspired the development of methodology to support further application
of MRS
–
–
–
–
–
–
–
Surface coils
Chemical shift imaging
Rotating frame imaging
Multinuclear spectroscopy
Hadamard spectroscopy
NMR pulse design methodology
Multimodality Optical-MR spectroscopy
Brit’s own acknowledgements